Nipocalimab treatment for pregnant women at risk of severe fetal anemia

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of nipocalimab compared to a placebo in reducing the risk of fetal anemia in pregnant women who have a history of severe hemolytic disease of the fetus and newborn (HDFN). Participants must be between 13 to 18 weeks of gestation and have documented evidence of HDFN in prior pregnancies. The study aims to determine if nipocalimab can improve outcomes for fetuses at risk of anemia due to maternal alloantibodies. The primary focus is on live neonates born to these participants.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Pregnant and an estimated gestational age (GA) (based on ultrasound dating) from Week 13\^0/7 to Week 18\^6/7 at randomization
* History of severe Hemolytic Disease of the Fetus and Newborn (HDFN) in a prior pregnancy defined as documented:

  1. fetal anemia as result of HDFN or fetal hydrops as result of HDFN or received greater than or equal to (\>=)1 IUT as a result of HDFN or
  2. fetal loss or neonatal death as a result of HDFN, with maternal alloantibody titers for Rhesus antigen D protein (RhD), Kell, Kell Rhesus antigen C protein (Rhc), Rhesus antigen E protein (RhE), or RhC antigen above the critical levels (anti-Kell \>=4; other \>=16) and evidence of an antigen-positive fetus
* During the current pregnancy, presence of maternal alloantibody to RhD, Rhc, RhE, or RhC antigen with titers above the critical level (anti-Kell \>= 4; other \>=16) based on the designated central lab results at screening
* Evidence of antigen-positivity corresponding to the current maternal alloantibody (RhD, Kell, Rhc, RhE, or RhC) confirmed by non-invasive antigen cell-free fetal DNA (cffDNA) performed at the central laboratory
* Have screening lab test results within values within the study protocol-specified parameters: a) albumin \>= lower limit of normal (LLN); b) alanine transaminase (AST) less than or equal to (\<=) 2 × upper limit of normal (ULN); c) alanine transaminase (ALT) \<=2 × ULN d) creatinine \<=0.8 milligrams per deciliter (mg/dL), SI: \<=70.7 micromole per liter (μmol/L), and Serum total immunoglobulins G (IgG) ≥ 600 mg/dL SI: \>=6 g/L
* Medically stable on the basis of physical examination, medical history, vital signs, 12-lead ECG, and clinical lab tests performed at screening

Exclusion Criteria:

* Currently pregnant with a multiple gestation (twins or more)
* Evidence of fetal anemia prior to randomization in the current pregnancy
* History of severe preeclampsia prior to GA Week 34 or severe fetal growth restriction (estimated fetal weight \<3rd percentile, based on local fetal growth normative standards) in a previous pregnancy
* Current uncontrolled hypertension
* History of myocardial infarction, unstable ischemic heart disease, or stroke
* Has any confirmed or suspected clinical immunodeficiency syndrome or has a family history of congenital or hereditary immunodeficiency unless confirmed absent in the participant
* Has inflammatory or autoimmune diseases requiring immunosuppressive therapies that may jeopardize the safety of the participant
* Currently has a malignancy or has a history of malignancy within 3 years before screening (with the exception of localized basal cell carcinoma and/or squamous cell carcinoma skin cancer that has been adequately treated with no evidence of recurrence for at least 3 months before the first study intervention administration or cervical carcinoma in situ that has been treated with no evidence of recurrence for at least 3 months before the first study intervention)
* Is currently receiving systemic corticosteroids or other immunosuppressants for disorders unrelated to the pregnancy
* Has received or planning to receive plasmapheresis, immunoadsorption therapy, intravenous immunoglobulin (IV Ig), or any immunoglobulin (Ig)G fragment crystallizable (Fc)-related protein therapeutics during the current pregnancy
* Has a severe infection including opportunistic infections
* Presence of abnormal (protocol-specified) hematologic lab values during screening
* History of an unprovoked pulmonary embolism or history of recurrent deep vein thrombosis (DVT)

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Where it's running

• University of California at San Diego
  La Jolla, California, United States Recruiting
• Kaiser Permanente Los Angeles Medical Center
  Los Angeles, California, United States Recruiting
• UC Davis School of Medicine
  Sacramento, California, United States Recruiting
• Childrens Hospital Colorado
  Aurora, Colorado, United States Recruiting
• University of Miami
  Miami, Florida, United States Recruiting
• Advocate Children's Hospital
  Park Ridge, Illinois, United States Recruiting

+19 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Study Contact
• Email: Participate-In-This-Study1@its.jnj.com
• Phone: 844-434-4210

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Nipocalimab in breast milk after a single IV dose in healthy lactating women

  This study tests how much nipocalimab shows up in breast milk after a single IV dose in healthy breastfeeding women.

  Recruiting Phase 1 Janssen Research & Development, LLC · Salt Lake City, Utah · NCT07669077

• Nipocalimab for adults with moderate to severe systemic lupus erythematosus

  This trial tests nipocalimab versus placebo in adults with moderate to severe lupus to see if it reduces disease activity and symptoms.

  Recruiting at 270 sites Phase 3 Janssen Research & Development, LLC · Beverly Hills, California and 271 other locations · NCT07438496

• Nipocalimab versus efgartigimod for generalized myasthenia gravis

  This trial will test whether nipocalimab or efgartigimod works better to reduce muscle weakness in adults with AChR-positive generalized myasthenia gravis who have meaningful symptoms despite stable therapy.

  Recruiting at 30 sites Phase 3 Janssen Research & Development, LLC · Fullerton, California and 30 other locations · NCT07217587

• Global registry for hemolytic disease of the fetus and newborn (HDFN)

  This project will follow pregnant people at risk for HDFN to see how often their fetuses or newborns develop anemia while receiving standard care.

  Recruiting at 16 sites Janssen Research & Development, LLC · Indianapolis, Indiana and 16 other locations · NCT07194070

• Measuring S100B Protein Levels in Newborns After Intrauterine Blood Transfusions for Fetal Anemia

  This study is testing if measuring a specific protein in the blood of newborns who received blood transfusions before birth can help predict the risk of brain problems later on.

  Recruiting Institute of Mother and Child, Warsaw, Poland · Warsaw · NCT06984445

• Evaluating nipocalimab and IVIG for preventing fetal and neonatal thrombocytopenia

  This study is testing if a new treatment called nipocalimab can help pregnant women with a history of fetal and neonatal thrombocytopenia keep their babies' platelet levels safe compared to standard treatment with IVIG.

  Recruiting at 37 sites Phase 3 Janssen Research & Development, LLC · Birmingham, Alabama and 37 other locations · NCT06533098

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.